This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Quan, Y.
Right arrow Articles by Wainberg, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Quan, Y.
Right arrow Articles by Wainberg, M. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2003, p. 747-754, Vol. 47, No. 2
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.2.747-754.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Lamivudine Can Exert a Modest Antiviral Effect against Human Immunodeficiency Virus Type 1 Containing the M184V Mutation

Yudong Quan, Bluma G. Brenner, Maureen Oliveira, and Mark A. Wainberg*

McGill University AIDS Centre, Lady Davis Institute-Jewish General Hospital, Montreal, Quebec, Canada

Received 28 June 2002/ Returned for modification 16 September 2002/ Accepted 4 November 2002

The M184V mutation in human immunodeficiency virus (HIV) reverse transcriptase is associated with high-level resistance to both (-)2',3'-dideoxy-3'-thiacytidine (3TC) and (-)2',3'-dideoxy-5-fluoro-3'-thiacytidine as well as low-level resistance to 2',3'-dideoxyinosine, 2',3'-dideoxycytidine, and abacavir. This mutation is also associated with diminished HIV replicative fitness as well as several functional changes in enzyme activity, including diminutions in polymerase processivity, pyrophosphorylysis, and nucleotide primer unblocking. Despite the fact that M184V encodes up to 1,000-fold resistance to 3TC, we asked whether this drug might still display some antiviral effect in regard to viruses containing this mutation. Cell-free assays revealed that high concentrations of 3TC triphosphate (i.e., >100 µM) could affect chain termination and/or inhibit purified reverse transcriptase containing the M184V substitution. This effect became more pronounced with elongation of reverse transcriptase products. In newly infected cells (i.e., peripheral blood mononuclear cells), we found that the amount of full-length reverse transcriptase product was diminished in the presence of 2 to 10 µM 3TC, although no decrease in the first product of the reverse transcriptase reaction, i.e., minus strong-stop DNA, was observed. In the presence of two other HIV inhibitors, e.g., nevirapine and indinavir, 3TC exerted additive effects in tissue culture at concentrations only marginally higher than the 50% inhibitory concentration (IC50). Reverse transcriptases cloned from clinical isolates harboring M184V in the context of multidrug resistance had similar IC50 values for 3TC triphosphate compared to reverse transcriptase containing only the M184V mutation. These results suggest that viruses containing M184V can retain a higher degree of sensitivity to 3TC than previously assumed.

* Corresponding author. Mailing address: McGill AIDS Centre, Lady Davis Institute/Jewish General Hospital, 3755 Cote Ste-Catherine Road, Montreal, Quebec Canada H3T 1E2. Phone: (514) 340-7536. Fax: (514) 340-7537. E-mail: mark.wainberg{at}mcgill.ca.

Antimicrobial Agents and Chemotherapy, February 2003, p. 747-754, Vol. 47, No. 2
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.2.747-754.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Dykes, C., Demeter, L. M. (2007). Clinical Significance of Human Immunodeficiency Virus Type 1 Replication Fitness. Clin. Microbiol. Rev. 20: 550-578 [Abstract] [Full Text]  
  • Bethell, R., De Muys, J., Lippens, J., Richard, A., Hamelin, B., Ren, C., Collins, P. (2007). In Vitro Interactions between Apricitabine and Other Deoxycytidine Analogues. Antimicrob. Agents Chemother. 51: 2948-2953 [Abstract] [Full Text]  
  • Perez-Bercoff, D., Wurtzer, S., Compain, S., Benech, H., Clavel, F. (2007). Human Immunodeficiency Virus Type 1: Resistance to Nucleoside Analogues and Replicative Capacity in Primary Human Macrophages. J. Virol. 81: 4540-4550 [Abstract] [Full Text]  
  • Chan-Tack, K. M., Edozien, A. (2006). Lamivudine Monotherapy in an HIV-Infected Patient With the M184V Mutation. J Int Assoc Physicians AIDS Care (Chic Ill) 5: 121-122  
  • Iyer, R. P., Jin, Y., Roland, A., Morrey, J. D., Mounir, S., Korba, B. (2004). Phosphorothioate Di- and Trinucleotides as a Novel Class of Anti-Hepatitis B Virus Agents. Antimicrob. Agents Chemother. 48: 2199-2205 [Abstract] [Full Text]  
  • Turner, D., Brenner, B., Wainberg, M. A. (2004). Relationships among various nucleoside resistance-conferring mutations in the reverse transcriptase of HIV-1. J Antimicrob Chemother 53: 53-57 [Abstract] [Full Text]  
  • Diallo, K., Gotte, M., Wainberg, M. A. (2003). Molecular Impact of the M184V Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase. Antimicrob. Agents Chemother. 47: 3377-3383 [Full Text]  
  • Diallo, K., Brenner, B., Oliveira, M., Moisi, D., Detorio, M., Gotte, M., Wainberg, M. A. (2003). The M184V Substitution in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Delays the Development of Resistance to Amprenavir and Efavirenz in Subtype B and C Clinical Isolates. Antimicrob. Agents Chemother. 47: 2376-2379 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»